170 related articles for article (PubMed ID: 23515289)
1. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
[TBL] [Abstract][Full Text] [Related]
2. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
Gallagher EJ; Alikhani N; Tobin-Hess A; Blank J; Buffin NJ; Zelenko Z; Tennagels N; Werner U; LeRoith D
Diabetes; 2013 Oct; 62(10):3553-60. PubMed ID: 23835331
[TBL] [Abstract][Full Text] [Related]
3. Highly specific role of the insulin receptor in breast cancer progression.
Rostoker R; Abelson S; Bitton-Worms K; Genkin I; Ben-Shmuel S; Dakwar M; Orr ZS; Caspi A; Tzukerman M; LeRoith D
Endocr Relat Cancer; 2015 Apr; 22(2):145-57. PubMed ID: 25694511
[TBL] [Abstract][Full Text] [Related]
4. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.
Ferguson RD; Novosyadlyy R; Fierz Y; Alikhani N; Sun H; Yakar S; Leroith D
Breast Cancer Res; 2012 Jan; 14(1):R8. PubMed ID: 22226054
[TBL] [Abstract][Full Text] [Related]
5. Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.
Zhang Q; Pan J; Lubet RA; Wang Y; You M
Mol Carcinog; 2015 Jun; 54 Suppl 1():E129-37. PubMed ID: 25163779
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
[TBL] [Abstract][Full Text] [Related]
8. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.
Novosyadlyy R; Lann DE; Vijayakumar A; Rowzee A; Lazzarino DA; Fierz Y; Carboni JM; Gottardis MM; Pennisi PA; Molinolo AA; Kurshan N; Mejia W; Santopietro S; Yakar S; Wood TL; LeRoith D
Cancer Res; 2010 Jan; 70(2):741-51. PubMed ID: 20068149
[TBL] [Abstract][Full Text] [Related]
9. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
10. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
11. Reversibility and recurrence of IGF-IR-induced mammary tumors.
Jones RA; Campbell CI; Wood GA; Petrik JJ; Moorehead RA
Oncogene; 2009 May; 28(21):2152-62. PubMed ID: 19377512
[TBL] [Abstract][Full Text] [Related]
12. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
13. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Dong L; Du M; Lv Q
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
[TBL] [Abstract][Full Text] [Related]
14. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma.
Ohshima-Hosoyama S; Hosoyama T; Nelon LD; Keller C
Biochem Biophys Res Commun; 2010 Sep; 399(4):727-32. PubMed ID: 20692232
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
16. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
Clin Cancer Res; 2006 Feb; 12(4):1383-91. PubMed ID: 16489097
[TBL] [Abstract][Full Text] [Related]
17. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
18. EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.
Zelenko Z; Gallagher EJ; Antoniou IM; Sachdev D; Nayak A; Yee D; LeRoith D
Endocr Relat Cancer; 2016 Sep; 23(9):747-58. PubMed ID: 27435064
[TBL] [Abstract][Full Text] [Related]
19. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.
Surmacz E; Bartucci M
J Exp Clin Cancer Res; 2004 Sep; 23(3):385-94. PubMed ID: 15595626
[TBL] [Abstract][Full Text] [Related]
20. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
